Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 12 studies | 49% ± 22% | |
GABAergic neuron | 5 studies | 24% ± 5% | |
astrocyte | 3 studies | 27% ± 5% | |
neuron | 3 studies | 26% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 19% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 577.47 | 2638 / 2642 | 96% | 20.05 | 676 / 705 |
kidney | 99% | 316.44 | 88 / 89 | 18% | 1.09 | 161 / 901 |
skin | 45% | 70.36 | 818 / 1809 | 46% | 5.02 | 219 / 472 |
intestine | 51% | 56.60 | 489 / 966 | 37% | 2.38 | 196 / 527 |
pancreas | 1% | 1.03 | 2 / 328 | 83% | 11.80 | 148 / 178 |
prostate | 48% | 44.66 | 117 / 245 | 36% | 2.23 | 179 / 502 |
breast | 1% | 0.78 | 4 / 459 | 77% | 8.53 | 861 / 1118 |
ovary | 3% | 2.06 | 5 / 180 | 66% | 6.90 | 285 / 430 |
uterus | 17% | 19.76 | 29 / 170 | 44% | 3.91 | 201 / 459 |
esophagus | 22% | 18.58 | 323 / 1445 | 31% | 1.86 | 57 / 183 |
stomach | 15% | 15.15 | 55 / 359 | 31% | 2.47 | 90 / 286 |
bladder | 5% | 2.29 | 1 / 21 | 40% | 3.06 | 203 / 504 |
lung | 1% | 1.14 | 8 / 578 | 40% | 2.36 | 461 / 1155 |
adrenal gland | 2% | 2.33 | 5 / 258 | 34% | 6.22 | 79 / 230 |
tonsil | 0% | 0 | 0 / 0 | 31% | 2.37 | 14 / 45 |
liver | 24% | 21.38 | 54 / 226 | 6% | 0.63 | 26 / 406 |
thymus | 6% | 3.74 | 37 / 653 | 17% | 1.31 | 100 / 605 |
adipose | 13% | 11.27 | 152 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.37 | 2 / 29 |
blood vessel | 2% | 1.60 | 25 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 0.65 | 9 / 929 | 0% | 0 | 0 / 0 |
heart | 1% | 0.68 | 8 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.24 | 2 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006644 | Biological process | phospholipid metabolic process |
GO_0090279 | Biological process | regulation of calcium ion import |
GO_0001835 | Biological process | blastocyst hatching |
GO_0046839 | Biological process | phospholipid dephosphorylation |
GO_0038096 | Biological process | Fc-gamma receptor signaling pathway involved in phagocytosis |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0000810 | Molecular function | diacylglycerol diphosphate phosphatase activity |
GO_0008195 | Molecular function | phosphatidate phosphatase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PLPP4 |
Protein name | Phospholipid phosphatase 4 (EC 3.1.3.4) (EC 3.6.1.75) (Phosphatidic acid phosphatase type 2 domain-containing protein 1A) |
Synonyms | DPPL2 PPAPDC1 PPAPDC1A |
Description | FUNCTION: Magnesium-independent phospholipid phosphatase with broad substrate specificity . Preferentially catalyzes the conversion of diacylglycerol pyrophosphate into phosphatidate but can also act on phosphatidate and lysophosphatidate . Phospholipid phosphatases are involved in both the synthesis of lipids and the degradation or generation of lipid-signaling molecules like diacylglycerol . . |
Accessions | ENST00000398250.6 [Q5VZY2-1] Q5VZY2 |